Semaglutide: Clinical Trials

8 trials for Semaglutide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 2 unknown, 1 not yet recruiting. 3 Phase 4, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 43Completed 1, Recruiting 1, Unknown 1
Phase 32Not yet recruiting 1, Recruiting 1
Phase 11Unknown 1

Follow Semaglutide: new trials by email Literature Review of Semaglutide trials Research Report on Semaglutide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
Semaglutide 2.4 mg - Pediatric Obesity, Metabolic and Bariatric Surgery
Phase 3RecruitingChildren's Hospital Los Angeles1502026-09-012026-09-02
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
Type 2 Diabetes, Obesity
RecruitingUniversity of Alberta502026-05-152026-07-17
Semaglutide Treatment in Type 1 Diabetes
Semaglutide 2.4mg, Semaglutide placebo - Obesity in Diabetes, Obesity/Therapy
Phase 3Not yet recruitingNordsjaellands Hospital1222025-10-012025-08-08
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
CompletedETH Zurich402025-03-152026-10-02
Subcutaneous Semaglutide in Systemic Scleroderma
Semaglutide Pen Injector - Scleroderma, Systemic, Fibrosis
Phase 1UnknownSecond Xiangya Hospital of Central South University102024-02-292024-03-05
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
Metformin Hydrochloride 500 MG, Semaglutide, 1.34 mg/mL, Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG - PCOS (Polycystic Ovary Syndrome), Semaglutide
Phase 4UnknownPeking University First Hospital752023-05-092024-03-25
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
semaglutide, caloric restriction - Type 2 Diabetes Mellitus (T2DM), Semaglutide
Phase 4RecruitingSecond Affiliated Hospital of Nanchang University1002023-02-102026-04-02
The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity
Semaglutide, Placebo - PCOS, Semaglutide
Phase 4CompletedUniversity Medical Centre Ljubljana302019-11-022023-09-08

Narrower conditions

Obesity (4)  ·  Diabetes Mellitus, Type 2 (2)  ·  Insulin Resistance (2)  ·  Weight Loss (2)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 1 (1)  ·  Dysgeusia (1)  ·  Fibrosis (1)  ·  Overweight (1)  ·  Pediatric Obesity (1)  ·  Polycystic Ovary Syndrome (1)  ·  Scleroderma, Systemic (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (7)  ·  Nutritional and Metabolic Diseases (6)  ·  Signs and Symptoms (6)  ·  Body Weight (5)  ·  Nutrition Disorders (5)  ·  Overnutrition (5)  ·  Endocrine System Diseases (4)  ·  Glucose Metabolism Disorders (4)  ·  Metabolic Diseases (4)  ·  Overweight (4)  ·  Body Weight Changes (2)  ·  Diabetes Mellitus (2)  ·  Hyperinsulinism (2)  ·  Adnexal Diseases (1)  ·  Autoimmune Diseases (1)

Interventions

semaglutide (5)  ·  Caloric Restriction (2)  ·  Exercise (1)  ·  Metformin (1)

Sponsors

Children's Hospital Los Angeles (1)  ·  ETH Zurich (1)  ·  Nordsjaellands Hospital (1)  ·  Peking University First Hospital (1)  ·  Second Affiliated Hospital of Nanchang University (1)  ·  Second Xiangya Hospital of Central South University (1)  ·  University Medical Centre Ljubljana (1)  ·  University of Alberta (1)

Countries

China (3)  ·  Canada (1)  ·  Denmark (1)  ·  Slovenia (1)  ·  Switzerland (1)  ·  United States (1)

Top investigators

Alaina Vidmar, MD (1)  ·  Christian Wolfrum, Prof. Dr. (1)  ·  Hao Ren, MD (1)  ·  Ke Chai, MD (1)  ·  Licong Liu, MD (1)  ·  Rong Xiao, MD (1)  ·  Ruixuan Zhu, MD (1)  ·  Thomas F Dejgaard, MD, ph.d., endocrinologist (1)  ·  Tingting Zhang, M.D. (1)  ·  Xiangning Qiu, MD (1)  ·  Yangfan Xiao, MD (1)  ·  Yaqian Shi, MD (1)  ·  Yi Wei, MD (1)  ·  Zhan Yi, MD (1)  ·  Zhuotong Zeng, MD (1)

Results publications

PMID 24362411, PMID 25885106, PMID 28834553, PMID 29703793, PMID 31229399, PMID 32442310, PMID 34281590, PMID 34455568, PMID 34732660, PMID 35829765, PMID 35951627, PMID 36060969

NIH funding

R01DK144100 (1)